TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20467151

Group type: EXPERIMENTAL
Intervention: Pitavastatin or Atorvastatin
Number of subjects: 252
Study: 18936764

Group type: EXPERIMENTAL
Intervention: DAG oil (10 g day(-1))
Number of subjects: 14

Group type: COMPARATOR
Intervention: TAG oil (10 g day(-1))
Number of subjects: 14
Study: 16424987

Group type: EXPERIMENTAL
Intervention: Rendezvous technique (videolaparoscopic cholecystectomy, intraoperative cholangiography, and EST during the surgical procedure)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Traditional method of bile duct cannulation (preoperative ERCP and EST)
Number of subjects: 256
Study: 14604931

Group type: EXPERIMENTAL
Intervention: 4.5 hour training programme promoting an obesity management model
Number of subjects: 843

Group type: COMPARATOR
Intervention: Control group (no training programme)
Number of subjects: 843
Study: 11044160

Group type: COMPARATOR
Intervention: Stapled haemorrhoidectomy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sutured haemorrhoidectomy
Number of subjects: 40
Study: 8723457

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 400 mg i.v. every 8 h
Number of subjects: 8

Group type: COMPARATOR
Intervention: Ciprofloxacin 400 mg i.v. every 12 h
Number of subjects: 8
Study: 1401997

Group type: EXPERIMENTAL
Intervention: IFN-gamma
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 14
Study: 3834009

Group type: EXPERIMENTAL
Intervention: Surgery with temporary AV-fistula
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: PTFE graft with AV-fistula
Number of subjects: 120
Study: 30226339

Group type: EXPERIMENTAL
Intervention: EVE group: 5 mg of 0.5% isobaric bupivacaine plus 15 Âµg of fentanyl injection followed by 10 mL of sterile saline injection.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group: 10 mg of 0.5% isobaric bupivacaine plus 15 Âµg of fentanyl injection.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups at the time of surgery start.
Number of subjects: 50
Study: 28008704

Group type: EXPERIMENTAL
Intervention: Family supportive nursing care
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 72
Study: 27187056

Group type: EXPERIMENTAL
Intervention: rTMS applied over site A (standard motor 'hotspot')
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: rTMS applied over site B (reorganized area)
Number of subjects: 30

Group type: COMPARATOR
Intervention: SHAM stimulation (occipital fissure)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: rTMS over site B compared to site A
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Open-label extension study of rTMS aimed at optimized target site
Number of subjects: 30
Study: 25375109

Group type: EXPERIMENTAL
Intervention: Curtin University's Activity, Food and Attitudes Program (CAFAP)
Number of subjects: 69
Study: 22488003

Group type: EXPERIMENTAL
Intervention: Dressing disruption
Number of subjects: 1419
Study: 20068567

Group type: EXPERIMENTAL
Intervention: weekly docetaxel with cisplatin and 5-fluorouracil (wTCF)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: weekly docetaxel with capecitabine (wTX)
Number of subjects: 106
Study: 18608841

Group type: EXPERIMENTAL
Intervention: Model demonstrations
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Physical practice with knowledge of performance
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination of model demonstrations and practice (with and without knowledge of performance)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination of model demonstrations and knowledge of performance practice
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Verbal instructions only
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Physical practice without knowledge of performance
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Model demonstrations with physical practice without knowledge of performance
Number of subjects: 120
Study: 16123681

Group type: EXPERIMENTAL
Intervention: peg‐interferon alpha‐2b plus ribavirin
Number of subjects: 383

Group type: COMPARATOR
Intervention: interferon alpha‐2b plus ribavirin
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: didanosine-containing antiretroviral regimens
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: stavudine or nucleoside reverse transcriptase inhibitor regimens not containing didanosine
Number of subjects: 383
Study: 12113586

Group type: EXPERIMENTAL
Intervention: Ofloxacin for three weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (non-treated patients)
Number of subjects: 90
Study: 10329092

Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 80
Study: 8955545

Group type: EXPERIMENTAL
Intervention: Participants with high scores on the SPQ during the shadowing task.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Participants with low scores on the SPQ during the shadowing task.
Number of subjects: 40
Study: 1898301

Group type: EXPERIMENTAL
Intervention: Temazepam (20 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6761122

Group type: EXPERIMENTAL
Intervention: 20 mg alinidine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 40 mg alinidine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 60 mg alinidine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30266575

Group type: EXPERIMENTAL
Intervention: Dietary portfolio (DP) comprising high-fibre, polyphenol-rich and vegetable-protein functional foods
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Dietary portfolio (DP)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 81
Study: 29417135

Group type: EXPERIMENTAL
Intervention: Guselkumab, 200 mg, by subcutaneous injection at weeks 0 and 4
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 27051309

Group type: EXPERIMENTAL
Intervention: Low-dose SFC (100 µg, two puffs daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: High-dose fluticasone propionate (FP) alone (500 µg, daily)
Number of subjects: 40
Study: 25280804

Group type: EXPERIMENTAL
Intervention: Outpatient interdisciplinary rehabilitation programme consisting of 6 weeks of intensive physiotherapy and individual occupational therapy as needed.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 0
Study: 22366983

Group type: EXPERIMENTAL
Intervention: sivelestat (ELP group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: placebo (control group)
Number of subjects: 50
Study: 20300683

Group type: EXPERIMENTAL
Intervention: Modified maxillary oblique plate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Twin-block
Number of subjects: 12
Study: 17336791

Group type: EXPERIMENTAL
Intervention: Food Cravings Questionnaires‐Trait (FCQ‐T)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Food Cravings Questionnaires‐State (FCQ‐S)
Number of subjects: 137
Study: 14754938

Group type: EXPERIMENTAL
Intervention: Female gender in a child with language delay
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Physician characteristics (female gender or being a pediatrician)
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Expression of parental concern
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Patient behaviors (disruptive vs avoidant)
Number of subjects: 1600
Study: 11605556

Group type: EXPERIMENTAL
Intervention: Normal vision condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ball‐only condition
Number of subjects: 0
Study: 9678811

Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg b.d. with clarithromycin (500 mg) and amoxycillin (1000 mg) b.d. for 14 days
Number of subjects: 160

Group type: COMPARATOR
Intervention: Nizatidine 300 mg b.d. with clarithromycin (500 mg) and amoxycillin (1000 mg) b.d. for 14 days
Number of subjects: 160
Study: 7992179

Group type: EXPERIMENTAL
Intervention: Electrosurgical trocars
Number of subjects: 25

Group type: COMPARATOR
Intervention: Mechanical trocars
Number of subjects: 25
Study: 2454343

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs (etmozin, quinidine, mexytil, allapinin, cordarone) used alone
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Combined treatment of antiarrhythmic drugs
Number of subjects: 13
Study: 31952554

Group type: EXPERIMENTAL
Intervention: Short-course therapy (SCT) - 5-day intravenous antimicrobial therapy if clinical improvement is observed
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional long-course therapy (LCT) - at least 7 days of intravenous antibiotics
Number of subjects: 150
Study: 31601228

Group type: EXPERIMENTAL
Intervention: Clinical mentorship program implemented in 48 health facilities
Number of subjects: 72

Group type: COMPARATOR
Intervention: No clinical mentorship program in 24 health facilities
Number of subjects: 72
Study: 28267469

Group type: EXPERIMENTAL
Intervention: Quality improvement intervention
Number of subjects: 15750
Study: 25223883

Group type: EXPERIMENTAL
Intervention: Low-frequency rTMS
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-frequency rTMS
Number of subjects: 24
Study: 23477576

Group type: EXPERIMENTAL
Intervention: HIV prevention information
Number of subjects: 1388

Group type: EXPERIMENTAL
Intervention: HIV prevention motivation
Number of subjects: 1388

Group type: EXPERIMENTAL
Intervention: HIV prevention behavioral skills
Number of subjects: 1388

Group type: EXPERIMENTAL
Intervention: HIV prevention information and motivation
Number of subjects: 1388
Study: 22147778

Group type: EXPERIMENTAL
Intervention: Helium-oxygen therapy
Number of subjects: 69

Group type: COMPARATOR
Intervention: Oxygen therapy
Number of subjects: 69
Study: 19567452

Group type: EXPERIMENTAL
Intervention: Acenocumarine 1 mg/day for 3 days before and 8 days after CVC insertion
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Dalteparin 5000 IU 2 h before and daily for 8 days after CVC insertion
Number of subjects: 450

Group type: COMPARATOR
Intervention: No anticoagulant treatment (NT)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Comparison between acenocumarine and dalteparin
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: All groups (Acenocumarine, Dalteparin, NT)
Number of subjects: 450
Study: 15824849

Group type: EXPERIMENTAL
Intervention: Calcium-based phosphate binders
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sevelamer
Number of subjects: 52
Study: 10512128

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion (CI) cisplatin 5 mg/m2/day plus etoposide 18 mg/m2/day for 5 days per week over 5 weeks with concurrent single daily fraction thoracic radiotherapy to 4500 cGy
Number of subjects: 19
Study: 8929242

Group type: EXPERIMENTAL
Intervention: ITF 282
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Iron sulphate
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Iron-polysterene sulphonate
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Reference drugs
Number of subjects: 1800
Study: 2202264

Group type: EXPERIMENTAL
Intervention: TUR + BCG (75 mg)
Number of subjects: 98

Group type: COMPARATOR
Intervention: TUR alone (control group)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: BCG (75 mg) for therapy of carcinoma in situ
Number of subjects: 98
Study: 6788318

Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 31888744

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Transcutaneous acupoint pseudo-electric stimulation (Sham TEAS)
Number of subjects: 88
Study: 30069864

Group type: EXPERIMENTAL
Intervention: Intravitreal Bevacizumab (IVB)
Number of subjects: 6354

Group type: COMPARATOR
Intervention: Intravitreal Ranibizumab (IVR)
Number of subjects: 6354
Study: 26809984

Group type: COMPARATOR
Intervention: Gefitinib monotherapy (G)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G)
Number of subjects: 236
Study: 24152888

Group type: EXPERIMENTAL
Intervention: Quadrupole butterfly coil (Bfly)
Number of subjects: 15

Group type: COMPARATOR
Intervention: MultiPurposeL coil (MPL)
Number of subjects: 15
Study: 22372508

Group type: EXPERIMENTAL
Intervention: valsartan + amlodipine + HCTZ
Number of subjects: 180

Group type: COMPARATOR
Intervention: olmesartan + amlodipine + HCTZ
Number of subjects: 180
Study: 19012880

Group type: EXPERIMENTAL
Intervention: Writing and information group (n=31)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Information control group (n=36)
Number of subjects: 67
Study: 17208587

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 15872123

Group type: EXPERIMENTAL
Intervention: DM-TIVA
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: DM-S
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control-TIVA
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control-S
Number of subjects: 30
Study: 12192468

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Number of subjects: 191
Study: 9664839

Group type: EXPERIMENTAL
Intervention: Modality variations in stimulus identification and code access processes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distance variations and end‐term variations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: End‐term and distance effects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modality and end‐term effects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimulus modality variation
Number of subjects: 0
Study: 7656958

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2568971

Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30919638

Group type: EXPERIMENTAL
Intervention: Ozonated water
Number of subjects: 30

Group type: COMPARATOR
Intervention: Chlorhexidine mouth-rinse
Number of subjects: 30
Study: 28159027

Group type: EXPERIMENTAL
Intervention: Face-to-face interview (FTFI)
Number of subjects: 616

Group type: COMPARATOR
Intervention: Computer-assisted self-interview (CASI)
Number of subjects: 616
Study: 26241292

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - new users of electronic devices
Number of subjects: 2

Group type: COMPARATOR
Intervention: Electronic Control Group (ECG) - former users of electronic devices
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Electronic Control Group (ECG)
Number of subjects: 2
Study: 23414724

Group type: EXPERIMENTAL
Intervention: Ethanol condition (body-weight-dependent amount of ethanol to achieve a blood alcohol concentration of 1.0‰)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sober condition (participants served as their own controls)
Number of subjects: 14
Study: 21332286

Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Liposomal amphotericin B (L-AmB)
Number of subjects: 0
Study: 18947861

Group type: EXPERIMENTAL
Intervention: Total laparoscopic hysterectomy (LPS)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Abdominal hysterectomy with lymphadenectomy (LPT)
Number of subjects: 159
Study: 17470822

Group type: EXPERIMENTAL
Intervention: Vitamin therapy (2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12)
Number of subjects: 5522

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5522
Study: 16586193

Group type: EXPERIMENTAL
Intervention: Indianapolis Vocational Intervention Program (IVIP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard support services
Number of subjects: 50
Study: 12472998

Group type: EXPERIMENTAL
Intervention: Braun Oral‐B 3D Excel power toothbrush (BPT)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Sonicare power toothbrush (SPT)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Philips Sensiflex 2000 power toothbrush (PPT)
Number of subjects: 67
Study: 9797188

Group type: EXPERIMENTAL
Intervention: 6 mg/kg L-NMMA
Number of subjects: 22

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: L-arginine (30 g over 30 min)
Number of subjects: 22
Study: 8634659

Group type: EXPERIMENTAL
Intervention: beta‐carotene (20 mg)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: DL-alpha-tocopheryl acetate (55 mg)
Number of subjects: 227

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 227
Study: 2758537

Group type: EXPERIMENTAL
Intervention: Fentanyl (1.5 or 3.0 microgram.kg‐1)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg.kg‐1)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Thiopentone (induction of anaesthesia)
Number of subjects: 150
Study: 789268

Group type: EXPERIMENTAL
Intervention: Intravenous cefazolin
Number of subjects: 28

Group type: COMPARATOR
Intervention: Intravenous cephalothin
Number of subjects: 28
Study: 31787409

Group type: EXPERIMENTAL
Intervention: Healthcare workers who encountered AEFI (n = 120)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Discussion of AEFI during the last supervisory visit
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Barriers to reporting AEFI
Number of subjects: 306
Study: 31588974

Group type: EXPERIMENTAL
Intervention: Endotracheal suctioning (ETS)
Number of subjects: 132

Group type: COMPARATOR
Intervention: No endotracheal suctioning (no-ETS)
Number of subjects: 132
Study: 28419884

Group type: EXPERIMENTAL
Intervention: Fish oil (2 g/d)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 401
Study: 25943360

Group type: EXPERIMENTAL
Intervention: Ringer's lactate
Number of subjects: 88

Group type: COMPARATOR
Intervention: Hydroxyethyl starch
Number of subjects: 88
Study: 22298434

Group type: EXPERIMENTAL
Intervention: Therapeutic alliance measured with Working Alliance Inventory after session 7
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pre-treatment patient variables including personality disorder pathology
Number of subjects: 100
Study: 22054415

Group type: EXPERIMENTAL
Intervention: Formula feeding
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Feeding on schedule
Number of subjects: 612
Study: 17899113

Group type: EXPERIMENTAL
Intervention: Intrastromal corneal ring
Number of subjects: 20

Group type: COMPARATOR
Intervention: No intrastromal corneal ring (Control)
Number of subjects: 20
Study: 17087839

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl 2 microg kg(‐1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (general anaesthesia and caudal block)
Number of subjects: 50
Study: 15041600

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg IV
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Dexamethasone 12 mg IV
Number of subjects: 240

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Droperidol 0.1 mg/mL with morphine in PCA
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg IV
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Dexamethasone 2 mg IV
Number of subjects: 240
Study: 11295924

Group type: EXPERIMENTAL
Intervention: Mucocutaneous biopsy specimens analyzed by light microscopy, immunohistochemical analysis, and microbiological analysis (standard viral culture and shell‐vial technique) in studies 1 and 2.
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Mucocutaneous biopsy specimens analyzed by light microscopy, immunohistochemical analysis, and microbiological analysis (standard viral culture and shell‐vial technique) in study 3.
Number of subjects: 56
Study: 8990448

Group type: EXPERIMENTAL
Intervention: Oral HRT (estradiol 2.0 mg/d + norethisterone acetate 1.0 mg/d)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Transdermal HRT (estradiol 50 micrograms/d + medroxyprogesterone acetate 10 mg/d)
Number of subjects: 26
Study: 8484508

Group type: EXPERIMENTAL
Intervention: Ketorolac, 60 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 60
Study: 3437794

Group type: EXPERIMENTAL
Intervention: 20 X 10(6) IU/m2 of recombinant interferon (rIFN)‐alpha‐2A, I.M., twice a week for 6 months
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 X 10(6) IU/m2 of recombinant interferon (rIFN)‐alpha‐2A, I.M., twice a week for 6 months
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low dose of rIFN
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High dose of rIFN
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Long-term rIFN‐alpha‐2A therapy
Number of subjects: 12
Study: 29471595

Group type: EXPERIMENTAL
Intervention: Procollagen-III peptide (PIIINP) levels
Number of subjects: 62

Group type: COMPARATOR
Intervention: T2DM patients with NAFLD
Number of subjects: 62
Study: 26842592

Group type: EXPERIMENTAL
Intervention: Ezetimibe
Number of subjects: 20

Group type: COMPARATOR
Intervention: Rosuvastatin
Number of subjects: 20

Group type: COMPARATOR
Intervention: High-fat diet loading
Number of subjects: 20
Study: 25171970

Group type: EXPERIMENTAL
Intervention: Echocardiography
Number of subjects: 685

Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Number of subjects: 685

Group type: EXPERIMENTAL
Intervention: Echocardiography and CT combined
Number of subjects: 685

Group type: EXPERIMENTAL
Intervention: Prediction for future prevalence
Number of subjects: 685
Study: 23524841

Group type: EXPERIMENTAL
Intervention: Aspirin (81, 162.5, 325, 650, or 1300 mg daily for 12 weeks)
Number of subjects: 37
Study: 19468757

Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estradiol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of Risedronate and Estradiol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18317236

Group type: EXPERIMENTAL
Intervention: Mannose-binding lectin (MBL) deficiency
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Low MBL levels
Number of subjects: 158
Study: 16899966

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural group intervention
Number of subjects: 30
Study: 14629688

Group type: EXPERIMENTAL
Intervention: Dysphoric students
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nondysphoric students
Number of subjects: 0